Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), gy decreased (Expand Search)
-
14321
Image 5_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg
Published 2024“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
-
14322
Table 1_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.docx
Published 2024“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
-
14323
Image 3_Low miR-936-mediated upregulation of Pim-3 drives sorafenib resistance in liver cancer through ferroptosis inhibition by activating the ANKRD18A/Src/NRF2 pathway.jpeg
Published 2024“…MiR-936 overexpression and GV102-Pim-3-shRNA significantly attenuated the activity of the ANKRD18A/Src/NRF2 pathway to decrease the expression of Ankyrin repeat domain-containing protein 18A (ANKRD18A), Src, and Nuclear factor (erythroid-derived 2)-like 2 (NRF2), especially decreasing NRF2 nuclear retention and transcriptional activity. …”
-
14324
Data Sheet 1_Oral immunotherapy for cow’s milk allergy in children: a systematic review and meta-analysis.docx
Published 2025“…Tolerance threshold at oral food challenges (OFC) increased following oral immunotherapy compared with a standard mean difference (SMD) of 3.58 (2.82–4.33). After oral immunotherapy, the antibody titers of cow milk protein sIgE (SMD -0.42, 95% CI: -0.72 to -0.11, I²=28.8%) and casein sIgE (SMD -0.54, 95% CI: -0.97 to -0.11, I²=0%) decreased. …”
-
14325
Table 1_Characteristics and trends of unintentional injuries among children and adolescents in Kunshan, China: a hospital-based retrospective study, 2018–2023.docx
Published 2025“…Unintentional injury cases decreased significantly during COVID-19 (2020–2022). …”
-
14326
Effect of HPC silencing on phase-locking of PFC neurons to local theta.
Published 2025“…Percentage of neurons significantly phase-locked to PFC theta oscillations (4–12 Hz) in the sample <b>(A)</b> and choice phase <b>(B)</b> during light-off and light-on trials. …”
-
14327
Data Sheet 1_Preoperative remote consultation for a green bariatric surgery: can telemedicine be safe for patients and sustainable for the environment?.pdf
Published 2025“…At one-year follow-up, the mean BMI decreased to 29 kg/m<sup>2</sup> (±3). In the revisional surgery group, percent excess weight loss reached 75.4% at one year.…”
-
14328
Ybx1 regulation of its target mRNAs is m<sup>5</sup>C-depdendent (Related to Fig 5).
Published 2025“…Data are presented as mean ± SEM: at least 3 replicates were analyzed for each experiment (<i>n</i> = 3); ns, not significant; by unpaired Student <i>t</i> test. …”
-
14329
<i>ADH7, FABP5, ALDH1A1, CRABP-2, PPARγ</i> and <i>VEGFA</i> mRNA and ADH7, FABP5, CRABP-2, PPARγ and VEGFA protein levels in limbal stromal cells (LSCs) and aniridia limbal stroma...
Published 2025“…Furthermore, 0.078 and 0.313 μg/mL travoprost treatment significantly decreased ADH7 protein levels in LSCs (p = 0.039; p < 0.001) and 0.313 μg/mL travoprost treatment significantly increased ADH7 protein levels in AN-LSCs, compared to their untreated controls (p = 0.039) <b>(B, C)</b>. …”
-
14330
Table 1_Bifidobacterium compound preparations as a supplementary treatment for severe ischemic stroke: a systematic review and meta-analysis.docx
Published 2025“…Regarding neurological function, the BCP combination group significantly increased the Glasgow Coma Scale score (MD = 1.86, 95% CI 1.17 to 2.56, p < 0.00001) and decreased the National Institutes of Health Stroke Scale score (MD = −2.17, 95% CI −3.35 to −0.99, p = 0.0003). …”
-
14331
Data Sheet 2_Adaptation of thoracic and lumbar curvature and spinal muscle activity under changing gravity.pdf
Published 2025“…</p>Results<p>Spinal flattening was observed during micro-gravity exposure, with changes most pronounced in the upper lumbar and lower thoracic spine. Mean-normalized area between the back and backpack decreased significantly in micro-gravity compared to earth-gravity (p = 0.001), but not during hyper-gravity (p = 1.00). …”
-
14332
Data Sheet 1_Adaptation of thoracic and lumbar curvature and spinal muscle activity under changing gravity.pdf
Published 2025“…</p>Results<p>Spinal flattening was observed during micro-gravity exposure, with changes most pronounced in the upper lumbar and lower thoracic spine. Mean-normalized area between the back and backpack decreased significantly in micro-gravity compared to earth-gravity (p = 0.001), but not during hyper-gravity (p = 1.00). …”
-
14333
Table 1_Assessment the relationship between health anxiety and iranian nurses’ quality of life: a cross-sectional study.docx
Published 2025“…</p>Conclusion<p>This study showed that there is a significant relationship between health anxiety and different dimensions of quality of life, so that the quality of life of nurses decreases with the increase of health anxiety.…”
-
14334
Data Sheet 1_Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systemat...
Published 2025“…PSCK9 inhibitors and potent statins significantly reduced LDL-C levels from baseline vs. placebo regardless of background therapy. …”
-
14335
Figure 2 from Metabolomic Biomarkers in Blood Samples Identify Cancers in a Mixed Population of Patients with Nonspecific Symptoms
Published 2025“…<b>B,</b> Difference spectrum showing regions that were increased in patients with solid tumors (red), decreased in patients with solid tumors (blue), or unchanged (gray). …”
-
14336
CLIC1 upregulation accelerates oxidative stress in oxygen and glucose deprivation/reoxygenation (OGD/R)-treated HT22 cells.
Published 2025“…<p>(a-c) The activities of SOD (a), CAT (b), and GSH-Px (c) were significantly reduced in OGD/R-treated HT22 cells compared to the control group, with the restoration of these antioxidant enzyme activities upon CLIC1 silencing. …”
-
14337
Western blot antibody information.
Published 2025“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
-
14338
Information on healthy and aniridia subjects.
Published 2025“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
-
14339
qPCR primers information.
Published 2025“…<i>PTGFR</i> and <i>JNK</i> mRNA levels, MMP9 and ADH7 protein levels increased significantly in AN-LSCs after 0.313 μg/mL travoprost treatment (p≤0.039), while NF-κB and ADH7 protein levels decreased significantly in LSCs using 0.313 μg/mL travoprost (p=0.039; p<0.001).…”
-
14340
Bias risk assessment of included studies.
Published 2025“…Compared to standard treatment, QJHTD significantly improved pulmonary function, with increases in FEV1 (MD = 0.32, 95% CI [0.25, 0.38], <i>p </i>= 0.000), FVC (MD = 0.30, 95% CI [0.22, 0.37], <i>p </i>= 0.000), FEV1/FVC (MD = 5.58, 95% CI [4.81, 6.34], <i>p </i>= 0.000), and PaO<sub>2</sub> (MD = 9.62, 95% CI [6.17, 13.08], <i>p </i>= 0.000), and a decrease in PaCO<sub>2</sub> (MD = -9.12, 95% CI [–11.96, –6.28], <i>p </i>= 0.000). …”